D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers

Completed · Phase 1

Conditions studied: Gout

In brief

This initial clinical study in the US will be a randomized, double-blind, placebo-controlled, single-dose, dose-escalation, and sequential cohort study to evaluate the safety, tolerability, PK and PD of D-0120-NA in fasting, healthy volunteers (HVs). In food effect cohort, subjects will each receive 2 doses of D-0120-NA in an open-label manner; once in the fasted state and once in the fed state.

Key facts

Study ID

NCT03291782

Run by

InventisBio Co., Ltd

People needed

39

Starts

2017-09-13

Expected to finish

2018-08-06

Last updated by the study team

2018-12-19

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects must be medically documented as healthy and acceptable at physical examination.
• Subjects serum uric acid level at screening ≥ 4.5 mg/dL.
• Subjects must have a BMI between 18.0 and 30.0 kg/m2 and a body weight of 50 kg or higher
• Subjects must have all laboratory parameters within the normal range or considered not clinically significant by the principal investigator.
• Subjects must have a normal urinalysis, eGFR, ECG or results considered not clinically significant by the principal investigator.
• Subjects are able to understand the study procedures and risks involved and must provide signed informed consent to participate in the study.

You may not qualify if…

• Any history or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urological, or psychiatric disorders.
• Any history or suspicion of kidney stones.
• Positive for HIV, Hepatitis B, and/or Hepatitis C.
• Subjects who have used prescription drugs, over-the-counter drugs, or herbal remedies within 14 days before Day 1 of study medication dosing.
• Undergone major surgery within 3 months prior to Day 1.
• Women who are pregnant or breastfeeding.
• Subjects who received any investigational test article within 5 half-lives or 30 days prior to Day 1 study medication dosing.
• Subjects who consumed Seville oranges- or grapefruit-containing foods or beverages within 7 days before Day 1 and during the entire study duration.
• Subjects with any condition that, in the judgment of the investigator, would place him/her at undue risk, or potentially compromise the results or interpretation of the study.

Where it is running

• Covance Daytona Beach Clinical Research Unit — Daytona Beach, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.